-
1.发明申请Process for the preparation of modification I of n-(1-methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridinesulfonamide 审中-公开制备n-（1-甲基乙基氨基羰基）-4-（3-甲基苯基氨基）-3-吡啶磺酰胺的改性I的方法公开(公告)号：US20060100439A1
公开(公告)日：2006-05-11
申请号：US10521609
申请日：2003-07-07
申请人： Darko Filic , Miljenko Dumic , Aleksandar Danilovski , Bozena Klepic , Ines Fistric , Marina Marinkovic , Jasna Horvat-Mikulcic
发明人： Darko Filic , Miljenko Dumic , Aleksandar Danilovski , Bozena Klepic , Ines Fistric , Marina Marinkovic , Jasna Horvat-Mikulcic
IPC分类号： C07D213/75
CPC分类号： C07D213/74
摘要： The invention relates to a new process for the preparation of modification I of torasemide by precipitation with acids from an alkaline extract of the original reaction mixture of the last phase in the synthesis of torasemide.
摘要翻译： 本发明涉及一种通过在合成托拉塞米的最后阶段的原始反应混合物的碱性提取物中用酸沉淀制备托拉塞米的修饰I的新方法。
-
2.发明授权Compositions of N-(methylethylaminocarbonyl)-4-(-3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosaccharides 失效N-（甲基乙基氨基羰基）-4-（ - 3-甲基苯基氨基）-3-吡啶基磺酰胺和环状低聚糖的组合物公开(公告)号：US07037928B2
公开(公告)日：2006-05-02
申请号：US10416303
申请日：2001-01-31
IPC分类号： A61K31/44 , C07D213/02
CPC分类号： A61K31/44 , A61K31/715 , A61K31/724 , A61K45/06 , A61K47/6951 , B82Y5/00 , A61K2300/00
摘要： The invention relates to compositions of N-(1-methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridylsul fonamide and cyclic oligosaccharides with increased release, to methods for their preparation, to pharmaceutical froms containing them as well as to their use.
摘要翻译： 本发明涉及N-（1-甲基乙基氨基羰基）-4-（3-甲基苯基氨基）-3-吡啶基磺酰胺和释放增加的环状寡糖，其制备方法，含有它们的药物以及它们的用途的组合物 。
-
公开(公告)号：US20070276015A1
公开(公告)日：2007-11-29
申请号：US11822274
申请日：2007-07-03
申请人： Darko Filic , Miljenko Dumic , Aleksandar Danilovski , Bozena Klepic , Ines Fistric , Marina Oresic , Jasna Horvat Mikulcic
发明人： Darko Filic , Miljenko Dumic , Aleksandar Danilovski , Bozena Klepic , Ines Fistric , Marina Oresic , Jasna Horvat Mikulcic
CPC分类号： A61K31/44 , C07D213/53 , C07D213/71 , C07D213/74
摘要： The present invention relates to the characterization of a new crystal modification III of torasemide, to a process for the preparation thereof by the use of controlled acidifying of alkaline solutions of torasemide with inorganic or organic acids with or without addition of a crystal seed, to its use as a raw material for the preparation of the crystal modification I of torasemide and of pharmaceutically acceptable salts of torasemide as well as to pharmaceutical forms containing this new crystal modification III of torasemide.
摘要翻译： 本发明涉及托拉塞米的新晶体改性III的表征，其制备方法是通过使用托拉塞米的碱性溶液与无机或有机酸（有或没有加入晶种）将其酸化至其 用作制备托拉塞米和托拉塞米的药学上可接受的盐的晶体改性I的原料以及含有托拉塞米的这种新的结晶改性III的药物形式。
-
公开(公告)号：US20070238759A1
公开(公告)日：2007-10-11
申请号：US11763156
申请日：2007-06-14
IPC分类号： C07D213/74 , A61K31/44
CPC分类号： C07D213/74
摘要： The invention relates to a novel polymorph V of torasemide, to a process for its preparation, to its use as a raw material for the preparation of crystalline modifications I and III of torasemide, to amorphous torasemide modifications and to pharmaceutically acceptable salts of torasemide, to pharmaceutical forms containing the said novel polymorph V of torasemide as the active ingredient as well as to its use.
摘要翻译： 本发明涉及托拉塞米的新型多晶型V，其制备方法，其用作制备托拉塞米的晶体修饰I和III的原料，其用于无定形托拉塞米改性和托拉塞米的药学上可接受的盐， 含有所述新型多晶型V的托拉塞米作为活性成分的药物形式及其用途。
-
公开(公告)号：US20060205951A1
公开(公告)日：2006-09-14
申请号：US11357109
申请日：2006-02-21
申请人： Darko Filic , Miljenko Dumic , Aleksandar Danilovski , Bozena Klepic , Ines Fistric , Marina Oresic , Jasna Horvat Mikulcic
发明人： Darko Filic , Miljenko Dumic , Aleksandar Danilovski , Bozena Klepic , Ines Fistric , Marina Oresic , Jasna Horvat Mikulcic
IPC分类号： C07D213/75
CPC分类号： A61K31/44 , C07D213/53 , C07D213/71 , C07D213/74
摘要： The present invention relates to the characterization of a new crystal modification III of torasemide, to a process for the preparation thereof by the use of controlled acidifying of alkaline solutions of torasemide with inorganic or organic acids with or without addition of a crystal seed, to its use as a raw material for the preparation of the crystal modification I of torasemide and of pharmaceutically acceptable salts of torasemide as well as to pharmaceutical forms containing this new crystal modification III of torasemide.
-
-
-
-
搜索结果
5 条记录 (耗时 0.012 秒)